Integra Q3 revenues down 0.7%, GAAP EPS $0.24; adjusts FY23 guidance lower

INTEGRA LIFESCIENCES HOLDINGS CORP

2023-Q3 EPS reported $0.59 revenue$1,144,534,000

Q3 revenue $382.4M, reported -0.7% YoY; organic ex-Boston +7.1%.
GAAP EPS $0.24 vs $0.60; adjusted EPS $0.76 vs $0.86.
Codman Specialty Surgical +7.4% organic; Tissue Technologies -15.1% organic due to Boston recall returns.
FY23 revenue guidance cut to $1.541-1.547B; adjusted EPS $3.10-3.14.
Boston facility restart on track for Q4'23; commercial distribution expected mid-to-late Q2'24.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

INTEGRA LIFESCIENCES HOLDINGS CORP reported third quarter ending September 30, 2023 results: revenue $382.4 million, net income $19.5 million, EPS $0.24 per diluted share.

Period: third quarter ending September 30, 2023
Revenue: $382.4 million
Net income: $19.5 million
EPS: $0.24 per diluted share
Result: reported results

Exact text from the filing

global medical technology company, today reported financial results for the third quarter ending September 30, 2023. Third Quarter 2023 Highlights • Third quarter revenues of $382.4 million declined 0.7% on a reported basis and declined 0.4% on an organic basis compared to the prior year and increased 7.1% on an organic basis excluding Boston • Third quarter GAAP

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

INTEGRA LIFESCIENCES HOLDINGS CORP filing history →

Source: SEC EDGAR

accession 0000917520-23-000069

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.